ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

1Q 2023 ZYNLONTA®1 net sales increased 15% and operating expenses decreased 19% year-over-year2; FY 2023 guidance reaffirmed for ZYNLONTA double-digit net sales growth and reduction in operating... | May 9, 2023

Related Keywords

China ,New Jersey ,United States ,Switzerland ,Deerfield ,London ,City Of ,United Kingdom ,Lausanne Biop ,Kristen Harrington Smith ,Mitsubishi Tanabe Pharma Corporation ,Company On Twitter ,Overland Pharmaceuticals ,Company Annual Report On Form ,Drug Administration ,China National Medical Products Administration ,Linkedin ,Group Purchasing Organization ,Development Rd Expenses ,Exchange Commission ,Ameet Mallik ,Chief Executive Officer ,Chief Commercial Officer ,Infrastructure Investment ,Jobs Act ,Healthcare Royalty Partners ,Adjusted Net ,San Francisco Bay Area ,Based Compensation Expense ,Facility Agreement ,Healthcare Royalty ,Private Securities Litigation Reform Act ,Swedish Orphan Biovitrum ,European Economic Area ,Healthcare Royalty Management ,Blue Owl ,Annual Report ,Consolidated Interim Statement ,Three Months Ended ,Consolidated Interim Balance Sheet ,Adc Therapeutics Sa Stock Exchange ,News ,Information ,Press Release ,Q ,023 ,Pet ,Sales ,Ncreased ,End ,Operating ,Expenses ,Ecreased ,Y ,Guidance ,Reaffirmed ,Or ,Zynlonta ,Growth ,Reduction ,N Adct Ch0499880968 ,